📊 BLGO Key Takeaways
Investment Thesis
BioLargo demonstrates severe operational distress with negative operating margins of -191.3% and negative free cash flow of -8.3M despite achieving 2,383.8% revenue growth. The company is consuming cash at an unsustainable rate with only 3.9M in cash reserves against 6.8M in liabilities, indicating critical liquidity risk. Deteriorating fundamentals combined with substantial operating losses and negative returns on equity and assets suggest the company is not viable in its current operational structure.
BLGO Strengths
- Exceptional revenue growth of 2,383.8% year-over-year demonstrates strong commercial traction
- Gross margin of 43.9% indicates viable unit economics and pricing power at the product level
- Moderate leverage with Debt/Equity ratio of 0.51x provides some balance sheet flexibility
BLGO Risks
- Severe cash burn with operating cash flow of -8.3M and only 3.9M in cash reserves suggests runway of less than 6 months
- Operating losses of -14.9M far exceed gross profit of 3.4M indicating unsustainable cost structure and lack of operational leverage
- Negative interest coverage ratio of -27.5x demonstrates inability to service debt from operating income; company dependent on cash reserves
- Negative ROE of -291.4% and ROA of -141.7% indicate value destruction and inefficient asset deployment
- Current ratio of 1.01x demonstrates critically tight liquidity with minimal buffer for operational disruptions
Key Metrics to Watch
- Operating cash flow trend - critical indicator of sustainable operations and path to profitability
- Monthly cash burn rate and cash runway - survival metric given current burn rates
- Gross profit dollars and operating expense ratio - whether revenue growth will eventually drive operational leverage
- Debt covenant compliance and refinancing needs - refinancing risk given negative EBITDA
- Path to operating profitability - specific milestones and timeline for reaching positive operating income
BLGO Financial Metrics
💡 AI Analyst Insight
BIOLARGO, INC. presents a mixed fundamental picture. Review the detailed metrics above to form your own investment thesis.
BLGO Profitability Ratios
BLGO vs Default Sector
How BIOLARGO, INC. compares to Default sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
BLGO Balance Sheet & Liquidity
BLGO 5-Year Financial Trend
5-Year Trend Summary: BIOLARGO, INC.'s revenue has grown significantly by 602% over the 5-year period, indicating strong business expansion. The most recent EPS of $-0.01 indicates the company is currently unprofitable.
BLGO Growth Metrics (YoY)
BLGO Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $1.1M | -$1.1M | $0.00 |
| Q2 2025 | $2.8M | -$780.0K | $0.00 |
| Q1 2025 | $3.3M | -$775.0K | $0.00 |
| Q3 2024 | $2.7M | -$494.0K | $0.00 |
| Q2 2024 | $1.4M | -$494.0K | $0.00 |
| Q1 2024 | $3.7M | -$494.0K | $0.00 |
| Q3 2023 | $1.5M | -$494.0K | $0.00 |
| Q2 2023 | $1.3M | -$494.0K | $-0.01 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
BLGO Capital Allocation
BLGO SEC Filings
Access official SEC EDGAR filings for BIOLARGO, INC. (CIK: 0000880242)
📋 Recent SEC Filings
❓ Frequently Asked Questions about BLGO
What is the AI rating for BLGO?
BIOLARGO, INC. (BLGO) has an AI rating of STRONG SELL with 92% confidence, based on fundamental analysis of SEC EDGAR filings.
What are BLGO's key strengths?
Exceptional revenue growth of 2,383.8% year-over-year demonstrates strong commercial traction. Gross margin of 43.9% indicates viable unit economics and pricing power at the product level.
What are the risks of investing in BLGO?
Severe cash burn with operating cash flow of -8.3M and only 3.9M in cash reserves suggests runway of less than 6 months. Operating losses of -14.9M far exceed gross profit of 3.4M indicating unsustainable cost structure and lack of operational leverage.
What is BLGO's revenue and growth?
BIOLARGO, INC. reported revenue of $7.8M.
Does BLGO pay dividends?
BIOLARGO, INC. does not currently pay dividends.
Where can I find BLGO SEC filings?
Official SEC filings for BIOLARGO, INC. (CIK: 0000880242) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is BLGO's EPS?
BIOLARGO, INC. has a diluted EPS of $0.00.
How is the AI analysis conducted?
Our AI (Claude) analyzes publicly available SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports to evaluate financial health, profitability ratios, balance sheet strength, and growth metrics.